Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID

Autor: Sander W Tas, Joep Killestein, Joost Raaphorst, Taco W Kuijpers, Alexandre E Voskuyl, Gertjan Wolbink, Theo Rispens, Anneke J van der Kooi, Anja Ten Brinke, Karina de Leeuw, Abraham Rutgers, Juan J Garcia-Vallejo, Frederike J Bemelman, YK Onno Teng, Phyllis I Spuls, Mark Löwenberg, Jelle de Wit, Diane van der Woude, Marcel W Bekkenk, Luuk Wieske, Esther Brusse, Laura Boekel, Filip Eftimov, Eileen W Stalman, Maurice Steenhuis, Sofie Keijzer, Olvi Cristianawati, Koos P J van Dam, Adriaan G Volkers, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Bo Broens, Barbara Horváth, Annabel M Ruiter, Matthias H Busch, Dirk Jan Hijnen, Niels J M Verstegen, Pieter A van Doorn, Jan JGM Verschuuren, Laura Y L Kummer, Ruth R Hagen, Christine Kreher, Lisan H Kuijper, Mariël C Duurland, Veronique A L Konijn, Carolien E van de Sandt, Laura Fernández Blanco, Amélie Bos, Charlotte Menage, Tineke Jorritsma, Jet van den Dijssel, Rivka de Jongh, Tom Ashhurst, Marit J van Gils, Mathieu Claireaux, Sija Marieke van Ham, Renée CF van Allaart, Adája E Baars, George Elias, Cécile ACM van Els, H Stephan Goedee, Geert RAM D’Haens, Papay BP Jallah, Elham S Mirfazeli, Jim BD Keijser, Lotte van Ouwerkerk, Pieter van Paassen, Agner R Parra Sanchez, W Ludo van der Pol, Corine RG Schreurs, R Bart Takkenberg, Koos AH Zwinderman

Publikováno v: RMD Open, Vol 10, Iss 4 (2024)

Objectives Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This raises concerns about the vulnerabi

Externí odkaz: https://doaj.org/article/afff65e4600e4deabe9d42545d2637c0

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Autor: Koos P. J. van Dam, Adriaan G. Volkers, Luuk Wieske, Eileen W. Stalman, Laura Y. L. Kummer, Zoé L. E. van Kempen, Joep Killestein, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, R. Bart Takkenberg, Geert R. A. M. D’Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renée C. F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, S. Marieke van Ham, Theo Rispens, Taco W. Kuijpers, Mark Löwenberg, Filip Eftimov, on behalf of the T2B! Immunity against SARS-CoV-2 study group

Publikováno v: BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-11 (2023)

Abstract Background Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-

Externí odkaz: https://doaj.org/article/8a6e2bdaa5404154a54ecf8fcb54843c

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Autor: Luuk Wieske, Laura Y. L. Kummer, Koos P. J. van Dam, Eileen W. Stalman, Anneke J. van der Kooi, Joost Raaphorst, Mark Löwenberg, R. Bart Takkenberg, Adriaan G. Volkers, Geert R. A. M. D’Haens, Sander W. Tas, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Joep Killestein, Zoé L. E. van Kempen, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Gertjan Wolbink, Laura Boekel, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, B. Papay Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirkjan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Theo Rispens, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Filip Eftimov, on behalf of the T2B! immunity against SARS-CoV-2 study group

Publikováno v: BMC Medicine, Vol 20, Iss 1, Pp 1-6 (2022)

Abstract Background Studies have suggested incremental short-term adverse events (AE) after repeated vaccination. In this report, we assessed occurrence and risk factors for short-term AEs following repeated SARS-CoV-2 vaccination in patients with va

Externí odkaz: https://doaj.org/article/67db8621c3964b7a9443d09b66e09e5f

Identification of Liver and Plasma microRNAs in Chronic Hepatitis B Virus infection

Autor: Vladimir V. Loukachov, Karel A. van Dort, Irma Maurer, R. Bart Takkenberg, Anniki de Niet, Henk W. Reesink, Sophie B. Willemse, Neeltje A. Kootstra

Publikováno v: Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)

Background and AimsWith current standard of care a functional cure for Chronic Hepatitis B (CHB) is only achieved in 1-3% of patients and therefore novel therapies are needed. Disease activity during CHB can be determined by a broad range of virologi

Externí odkaz: https://doaj.org/article/7d1b1f66e52d4143b82e49dffa1fa3d9

Relief of symptoms and quality of life after conservative versus surgical treatment of benign liver tumors (CONSULT): a retrospective propensity score matched study

Autor: Alicia Furumaya, Belle V. van Rosmalen, Jan Jaap de Graeff, Marcel J. van der Poel, D. Sandjai Ramsoekh, Geert Kazemier, Joanne Verheij, R. Bart Takkenberg, Marc G. Besselink, Joris I. Erdmann, Thomas M. van Gulik

Publikováno v: HPB, 25(6), 711-720. John Wiley and Sons Inc.
Furumaya, A, van Rosmalen, B V, de Graeff, J J, van der Poel, M J, Ramsoekh, D S, Kazemier, G, Verheij, J, Takkenberg, R B, Besselink, M G, Erdmann, J I & van Gulik, T M 2023, ' Relief of symptoms and quality of life after conservative versus surgical treatment of benign liver tumors (CONSULT) : a retrospective propensity score matched study ', HPB, vol. 25, no. 6, pp. 711-720 . https://doi.org/10.1016/j.hpb.2023.02.019
HPB: The official journal of the International Hepato Pancreato Biliary Association, 25(6), 711-720. John Wiley and Sons Inc.

BACKGROUND: Surgery can be considered for selected patients with benign liver tumours (BLT). The aim of this study was to compare symptoms and quality of life (QoL) after conservative and surgical management of BLT. METHODS: In this dual-site cross-s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49259e24a06794831b4d635d3e0e288c
https://research.vumc.nl/en/publications/eb27fab9-5d37-47bd-9b3f-59ec2ab52d8f